According to a recently released report from Future Market Insights, the oxycodone market size is projected to exceed a valuation of US$ 8.92 billion by 2033. This marks a significant increase from its current value of US$ 5.11 billion in 2023. The substantial growth is primarily attributed to the escalating demand for efficient pain management remedies. The sales of oxycodone are likely to consistently rise at a CAGR of 5.7% between 2023 and 2033.
Oxycodone has been a widely prescribed opioid medication, contributing to the growth of the opioid market. However, due to concerns about misuse, addiction, and the opioid crisis, the market has faced increased scrutiny and regulatory interventions in recent years. As a result, the growth of the oxycodone market has been influenced by changing prescribing practices and regulations aimed at curbing opioid abuse.
Oxycodone is a potent opioid analgesic prescribed for moderate to severe pain management. As the population ages and the prevalence of chronic pain conditions such as arthritis and cancer increases, the demand for pain medications like oxycodone can grow.
The development of abuse-deterrent formulations of oxycodone, aimed at reducing the potential for misuse and abuse, has driven market growth. By introducing technologies that make it harder to crush, dissolve, or extract the active ingredient, pharmaceutical companies have sought to address concerns related to opioid abuse while maintaining access to effective pain management options.
The expiration of patents on branded oxycodone formulations has allowed for the entry of generic versions into the market. Generic competition can lead to lower prices, increased market penetration, and expanded access to oxycodone.
While oxycodone has been beneficial for many patients, it has also been associated with misuse, addiction, and overdose. The opioid epidemic, characterized by a surge in opioid-related deaths and addiction rates, has led to increased scrutiny and regulatory interventions. These include prescribing guidelines, monitoring programs, and stricter regulations on the production, distribution, and prescription of opioids.
The ongoing opioid epidemic, fueled partly by the overuse and misuse of prescription opioids, has raised significant public health concerns. The addictive nature of oxycodone and its potential for abuse has led to increased scrutiny and negative perception among the general public. This can result in reduced demand and stricter regulations, affecting the oxycodone market.
Advancements in drug delivery systems, such as extended-release formulations, can provide patients with prolonged pain relief and better convenience. Pharmaceutical companies can explore innovative delivery methods for oxycodone to enhance patient compliance and reduce the risk of misuse.
| Attributes | Details |
|---|---|
| Current Year Value (2023) | US$ 5.11 billion |
| Expected Forecast Value (2033) | US$ 8.92 billion |
| Projected CAGR (2023 to 2033) | 5.7% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
FMI's findings reveal that the market experienced a CAGR of 4.8% during the period spanning from 2018 to 2022, reaching a substantial market size of US$ 4.84 billion. Historically, there has been a significant increase in the prescription rates of opioids like oxycodone. Factors such as improved recognition and treatment of pain, aggressive marketing by pharmaceutical companies, and changes in prescribing practices have contributed to the growth of the oxycodone market.
The demand for pain management medication is consistently rising, creating prospects for the expansion of the oxycodone market. The growth trend is expected to continue in response to increasing healthcare spending globally. Considering this, the rising cases of chronic ailments such as rheumatoid arthritis are set to rev up growth opportunities for the market.
Oxycodone is a type of opioid consumed for pain management, anesthesia, and de-addiction. There are typically two forms of oxycodone based on their components: one with a long-acting component and the other with a short-acting component.
They are also known to provide relief after operations, surgeries, and other medical conditions, thereby boosting the demand for oxycodone in the global market. The rising number of chronic diseases such as fibromyalgia, arthritis, lower back pain, and others is accelerating the demand for pain-relieving opioids.
The demand for oxycodone is expected to rise globally as it is prescribed as an analgesic for post-operative pain, HIV, and cancer medication. According to the Centers for Disease Control and Prevention, 239 million surgeries were conducted in 2013. Around 65% of patients experienced moderate to severe post-operative pain, thus bolstering the adoption of oxycodone as an opioid pain management drug.
The global oxycodone market is expected to face certain restraints due to increased opioid abuse and mortality. In 2017, opioids were responsible for 66% of drug overdose deaths in the United States alone. However, in the coming years, the market is likely to benefit from government support and the development of new drugs that do not cause addiction.
The opioid crisis has prompted a shift in focus toward non-opioid and alternative pain management strategies. There is increasing interest in developing non-addictive pain medications or non-pharmacological interventions. Pharmaceutical companies can explore research and development opportunities in this area while ensuring patient safety and efficacy.
The growth of the oxycodone market is being shaped by the rising number of chronic disorders. It is commonly prescribed for post-surgery pain management. One significant driving factor is the increasing prevalence of Parkinson's syndrome.
According to BlueCross BlueShield, the prevalence of Parkinson's disease is gradually rising among young adults. Additionally, the Parkinson's Foundation reports that about 1 million people in the United States are living with the condition.
Patients with Parkinson's disease experiencing severe pain are sometimes prescribed long-acting oxycodone treatment, which has shown clinical improvements compared to a placebo.
Oxycodone also benefits patients with rheumatic conditions and cancer, as it helps improve pain management. Moreover, it is primarily used as a pain reliever after operations and surgeries, gaining momentum from these advancements.
Considering these factors, the increasing application of oxycodone in pain management indicates potential for market expansion in the near future. Restrains Give Way to New Development in the Global Oxycodone Market
Opioids are primarily used for pain relief; however, their addictive nature is a significant concern. While they offer cost-effective solutions for patients suffering from pain caused by various ailments, their addictive properties make them susceptible to abuse.
The consumption of opioids can lead to various side effects, including euphoria, slowed breathing, nausea, constipation, drowsiness, and confusion. To address the issue of addiction associated with opioids, there are ongoing research and development activities, supported by government reimbursement, aimed at developing oxycodone drugs that can help prevent addiction. These efforts are expected to create new opportunities for market growth during the forecast period.
The market is likely to experience growth due to the increase in new drug applications and the presence of pipeline products in pharmaceutical companies.
Principal Consultant
| Countries | 2022 Value Share in Global Market |
|---|---|
| United States | 91.3% |
| Japan | 23.7% |
The United States oxycodone market has witnessed significant growth in recent years, driven by factors such as
The United States is projected to maintain its position as a leader in the global market due to its substantial purchasing power derived from its large economy. According to the National Health Accounts by Centers for Medicare & Medicaid Services (CMS), healthcare spending in the country experienced a growth rate of 4.6% in 2019.
With healthcare expenditure expected to continue rising, there is likely to be a corresponding increase in the demand for oxycodone in the United States. This demand is projected to be driven by the escalating prevalence of chronic diseases in the country.
In response to the opioid crisis, the United States government has implemented stricter regulations and policies to control the prescribing and dispensing opioids, including oxycodone. These measures aim to curb misuse, abuse, and diversion of these drugs while ensuring access for patients in genuine need.
The United States has been grappling with an opioid epidemic, and oxycodone has played a significant role in the crisis. The misuse and abuse of opioids, including oxycodone, have led to a surge in addiction, overdoses, and fatalities. As a result, there has been a heightened focus on monitoring, prevention, and treatment programs nationwide.
The market in the United States is further strengthened by the presence of key players such as Purdue Pharma, Pfizer Inc., Janssen Pharmaceuticals Inc., Endo Pharmaceuticals, and others. Consequently, the oxycodone market in the United States is anticipated to exhibit promising growth in the forthcoming years.
Japan has one of the world's largest aging populations. Older adults are more likely to suffer from chronic pain conditions like cancer-related pain and osteoarthritis. The rise in the elderly population has contributed to the increased demand for pain management medications, including oxycodone.
There has been a shift in attitudes toward pain management in Japan. Traditionally, there was a reluctance to use opioids due to concerns about addiction and side effects. However, there is now a growing acceptance of opioids as a necessary treatment option for patients with severe pain, which has positively impacted the Japan oxycodone market.
Cancer rates in Japan have been steadily rising, leading to an increased demand for pain medications. Oxycodone is often prescribed to cancer patients experiencing severe pain, and this trend has contributed to the market growth.
The government has implemented strict regulations and monitoring systems to prevent misuse and diversion of opioids. The Act on the Rational Use and Proper Dispensing of Narcotics and Psychotropics ensure that opioids, including oxycodone, are prescribed and dispensed under close supervision.
| Countries | Value CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 5.5% |
| China | 5.6% |
| India | 4.1% |
A shift toward alternative pain management strategies influences the United Kingdom oxycodone market. The country has witnessed a rise in the prescription rates of oxycodone over the past decade. This phenomenon can be ascribed to a range of factors, including
According to the Office of National Statistics in the United Kingdom, healthcare expenditure in 2018 amounted to about US$ 230 billion, accounting for 10% of the country's total expenditure. Government financing of healthcare experienced a growth rate of 2.0%.
The increase in healthcare expenditure in the United Kingdom can be attributed to the rising prevalence of chronic diseases. Additionally, improved access to information has led to increased awareness among individuals about various medical conditions, resulting in a greater willingness to invest in advanced healthcare.
The misuse and addiction to oxycodone have become a key concern in the country. The rise in misuse has led to increased hospital admissions, overdose cases, and fatalities. The government and healthcare organizations have been taking measures to address this issue.
The government has taken several steps to address the opioid crisis, including the establishment of the Opioid Painkiller Addiction Working Group. This group aims to develop prevention, treatment, and recovery support strategies for individuals affected by opioid addiction.
These factors are expected to have a positive impact on the United Kingdom market, creating a favorable environment for the growth of oxycodone sales.
The rising prevalence of chronic pain conditions, such as cancer, arthritis, and neuropathy, has fueled the demand for effective pain management solutions in China, including oxycodone. The aging population contributes to the growing burden of chronic pain, driving the market growth. Additionally, the improving standard of living and increasing awareness about pain management have contributed to the market growth.
There has been an increased awareness and acceptance of opioid analgesics, including oxycodone, among healthcare professionals and patients in China. This shift is attributed to improved education about pain management, the effectiveness of opioids, and the availability of newer formulations.
China has witnessed significant changes in its regulatory environment concerning opioid medications. The government has implemented stricter controls and monitoring systems to prevent misuse, diversion, and addiction to opioids, including oxycodone. These measures aim to strike a balance between patient access to pain relief and preventing substance abuse.
The market in China has witnessed consolidation, with a few key pharmaceutical companies dominating the market. These companies have focused on developing innovative formulations, enhancing their distribution networks, and expanding their market reach.
The India oxycodone market has experienced significant growth in recent years, driven by
Chronic pain conditions, such as cancer-related pain, osteoarthritis, and post-operative pain, have risen in India. This trend has fueled the demand for oxycodone as an effective pain management option.
According to the Indian Council of Medical Research (ICMR) and India's National Centre for Disease Informatics and Research, the number of cancer cases in males alone is projected to increase from approximately 679,421 to an estimated 763,575 by 2025.
The escalating number of cancer cases is expected to contribute to the growing demand for effective pain management solutions. This trend is expected to positively impact the growth of the oxycodone market in India. Additionally, the expansion of the healthcare sector to meet the increasing healthcare requirements of the population is likely to create further opportunities for growth in the country.
India has a rapidly aging population, resulting in a higher incidence of age-related diseases and chronic pain conditions. Older people often require long-term pain management, leading to an increased demand for oxycodone.
The Narcotic Drugs and Psychotropic Substances Act 1985 regulates the sale, distribution, and use of oxycodone in India. The government has implemented stringent regulations to prevent the misuse and diversion of opioids while ensuring access to pain management for legitimate patients.
The Indian government has recognized the importance of palliative care and has taken steps to improve access to pain management services. This focus on palliative care has led to increased use of opioids like oxycodone for providing relief to patients with chronic pain.
| Segment | Forecasted CAGR (2023 to 2033) |
|---|---|
| Long Acting Oxycodone | 70.31% |
| Pain Management | 78.68% |
| Retail Pharmacies | 75.8% |
Long acting oxycodone is anticipated to experience greater sales compared to short-acting oxycodone due to several advantages it offers. One key advantage is the reduced dosing frequency, providing extended pain relief over longer periods. This extended treatment is especially beneficial for patients with persistent pain levels and for those who have not found satisfactory pain relief from non-opioid treatments.
Long acting oxycodone is designed to provide around-the-clock pain relief, typically lasting for 12 to 24 hours. This extended duration of action helps maintain a more stable blood concentration of the medication, leading to better pain control and reduced fluctuations in pain intensity.
The extended-release formulation allows for individualized dosing, with different strengths available to match patients' specific needs. Healthcare providers can select an appropriate dosage based on the severity of the pain and the patient's response to previous treatments.
Long-acting oxycodone is expected to witness an increase in demand due to its ability to maintain consistent and prolonged levels of the drug in the bloodstream, resulting in reduced peak and trough fluctuations. Furthermore, the improved dosing schedule of long-acting oxycodone allows patients to have a more structured medication routine, minimizing the need to constantly watch the clock between doses.
Oxycodone is a potent opioid analgesic commonly prescribed for managing moderate to severe pain. There is a significant global burden of pain-related conditions such as postoperative, cancer, and chronic non-cancer pain. The demand for effective pain management solutions drives the use of oxycodone in the pain management application segment.
Oxycodone is known for its strong analgesic properties. It acts on the central nervous system to alleviate pain by binding to opioid receptors in the brain and spinal cord. This makes it effective in managing various types of pain, including acute and chronic pain. The drug's potency and effectiveness contribute to its dominance in the pain management segment.
In severe pain that is not adequately controlled by other analgesics, oxycodone may be prescribed as a last resort. Alternatives to oxycodone, such as non-opioid analgesics or weaker opioids, may not relieve pain in certain situations. Consequently, oxycodone remains a preferred choice for pain management in cases where other options are inadequate.
Retail pharmacies are widely available and easily accessible to the general public. Patients can visit these pharmacies to obtain prescribed medications, including oxycodone. The convenience and proximity of retail pharmacies make them a popular choice for patients seeking pain relief medications.
Retail pharmacies are subject to strict regulations and oversight by government agencies, such as the Drug Enforcement Administration (DEA) in the United States. These regulations ensure proper handling, storage, and dispensing of controlled substances like oxycodone, making retail pharmacies a trusted source for patients and healthcare providers.
Retail pharmacies often provide additional services, such as patient counseling and education about medication use, potential side effects, and precautions. This can help promote responsible and safe usage of oxycodone, reducing the risks associated with its misuse or abuse.
Retail pharmacies have well-established supply chain management systems that allow them to maintain inventory and restock medications efficiently. This ensures a steady and reliable supply of oxycodone to meet the demands of patients.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global oxycodone market is highly fragmented as there are numerous notable players operating in the market. Key strategies that market players are using to gain an edge include:
In addition to the strategies mentioned above, oxycodone market players are also focusing on developing new delivery methods for oxycodone. For example, certain companies are developing oxycodone patches that can be applied to the skin, while others are developing oxycodone nasal sprays. These new delivery methods offer several advantages over traditional oral formulations of oxycodone, such as faster onset of action, improved pain relief, and reduced risk of abuse.
Recent Developments by Key Oxycodone Market Players:
Leading Oxycodone Manufacturers as Profiled by FMI include:
The net worth of the oxycodone market is expected to be US$ 8.92 billion by 2033.
The market is calculated to expand at a CAGR of 5.7% through 2033.
The market expanded at a CAGR of 5.7% from 2018 to 2022.
High occurrence of chronic pain conditions and increasing focus on the awareness programs.
The leading manufacturers are Purdue Pharma L.P, Daiichi Sankyo, and Acorda Therapeutics.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Product Life Cycle Analysis 3.5. Supply Chain Analysis 3.5.1. Supply Side Participants and their Roles 3.5.1.1. Producers 3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers) 3.5.1.3. Wholesalers and Distributors 3.5.2. Value Added and Value Created at Node in the Supply Chain 3.5.3. List of Raw Material Suppliers 3.5.4. List of Existing and Potential Buyer’s 3.6. Investment Feasibility Matrix 3.7. Value Chain Analysis 3.7.1. Profit Margin Analysis 3.7.2. Wholesalers and Distributors 3.7.3. Retailers 3.8. PESTLE and Porter’s Analysis 3.9. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries 3.10. Regional Parent Market Outlook 3.11. Production and Consumption Statistics 3.12. Import and Export Statistics 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Type, 2023 to 2033 5.3.1. Long-acting oxycodone 5.3.2. Short-acting oxycodone 5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033 6.3.1. Pain Management 6.3.2. De-addiction 6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Type 9.2.3. By Application 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Type 9.3.3. By Application 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Type 10.2.3. By Application 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Type 10.3.3. By Application 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. UK 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Type 11.2.3. By Application 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Type 11.3.3. By Application 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Type 12.2.3. By Application 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Type 12.3.3. By Application 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Type 13.2.3. By Application 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Type 13.3.3. By Application 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Type 14.2.3. By Application 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Type 14.3.3. By Application 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Type 15.2.3. By Application 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Type 15.3.3. By Application 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Type 16.1.2.2. By Application 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Type 16.2.2.2. By Application 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Type 16.3.2.2. By Application 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Type 16.4.2.2. By Application 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Type 16.5.2.2. By Application 16.5.2.3. By Distribution Channel 16.6. UK 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Type 16.6.2.2. By Application 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Type 16.7.2.2. By Application 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Type 16.8.2.2. By Application 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Type 16.9.2.2. By Application 16.9.2.3. By Distribution Channel 16.10. China 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Type 16.10.2.2. By Application 16.10.2.3. By Distribution Channel 16.11. Japan 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Type 16.11.2.2. By Application 16.11.2.3. By Distribution Channel 16.12. South Korea 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Type 16.12.2.2. By Application 16.12.2.3. By Distribution Channel 16.13. Singapore 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Type 16.13.2.2. By Application 16.13.2.3. By Distribution Channel 16.14. Thailand 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Type 16.14.2.2. By Application 16.14.2.3. By Distribution Channel 16.15. Indonesia 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Type 16.15.2.2. By Application 16.15.2.3. By Distribution Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Type 16.16.2.2. By Application 16.16.2.3. By Distribution Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Type 16.17.2.2. By Application 16.17.2.3. By Distribution Channel 16.18. GCC Countries 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Type 16.18.2.2. By Application 16.18.2.3. By Distribution Channel 16.19. South Africa 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Type 16.19.2.2. By Application 16.19.2.3. By Distribution Channel 16.20. Israel 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Type 16.20.2.2. By Application 16.20.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Type 17.3.3. By Application 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Teva Pharmaceutical Industries Ltd. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.1.5.2. Product Strategy 18.1.1.5.3. Channel Strategy 18.1.2. Purdue Pharma L.P 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.2.5.2. Product Strategy 18.1.2.5.3. Channel Strategy 18.1.3. Daiichi Sankyo 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.3.5.2. Product Strategy 18.1.3.5.3. Channel Strategy 18.1.4. Acorda Therapeutics 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.4.5.2. Product Strategy 18.1.4.5.3. Channel Strategy 18.1.5. Teikoku Pharma USA, Inc. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.5.5.2. Product Strategy 18.1.5.5.3. Channel Strategy 18.1.6. Mylan N.V 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.6.5.2. Product Strategy 18.1.6.5.3. Channel Strategy 18.1.7. Endo Pharmaceuticals Inc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.7.5.2. Product Strategy 18.1.7.5.3. Channel Strategy 18.1.8. Janssen Pharmaceuticals, Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.8.5.2. Product Strategy 18.1.8.5.3. Channel Strategy 18.1.9. Johnson & Johnson 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.9.5.2. Product Strategy 18.1.9.5.3. Channel Strategy 18.1.10. Pfizer Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.10.5.2. Product Strategy 18.1.10.5.3. Channel Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Oxycodone Market
